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Prevention and Control of Influenza
Recommendations of the Advisory Committee
on Immunization Practices (ACIP)
Summary
This report updates the 2000 recommendations by the Advisory Committee
on Immunization Practices (ACIP) on the use of influenza vaccine and antiviral
agents (MMWR  2000;49[No. RR-3]:1–38). The 2001 recommendations include
new or updated information regarding a) the cost-effectiveness of influenza
vaccination; b) the influenza vaccine supply; c) neuraminidase-inhibitor antiviral
drugs; d) the 2001–2002 trivalent vaccine virus strains, which are A/Moscow/10/
99 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, and B/Sichuan/379/99-like
strains; and e) extension of the optimal time period for vaccination through
November. A link to this report and other information regarding influenza can be
accessed at the website for the Influenza Branch, Division of Viral and Rickettsial
Diseases, National Center for Infectious Diseases, CDC at <http://www.cdc.gov/
ncidod/diseases/flu/fluvirus.htm>.
INTRODUCTION
Epidemics of influenza typically occur during the winter months and are respon-
sible for an average of approximately 20,000 deaths per year in the United States (1,2 ).
Influenza viruses also can cause pandemics, during which rates of illness and death
from influenza-related complications can increase dramatically worldwide. Influenza
viruses cause disease among all age groups (3–5 ). Rates of infection are highest among
children, but rates of serious illness and death are highest among persons aged >65
years and persons of any age who have medical conditions that place them at increased
risk for complications from influenza (3,6–8 ).
Influenza vaccination is the primary method for preventing influenza and its severe
complications. In this report from the Advisory Committee on Immunization Practices
(ACIP), the primary target groups recommended for annual vaccination are a) groups
that are at increased risk for influenza-related complications (e.g., persons aged >65
years and persons of any age with certain chronic medical conditions); b) the group
aged 50–64 years because this group has an elevated prevalence of certain chronic
medical conditions; and c) persons who live with or care for persons at high risk (e.g.,
health-care workers and household members who have frequent contact with persons
at high risk and can transmit influenza infections to these persons at high risk). Vaccina-
tion is associated with reductions in influenza-related respiratory illness and physician
visits among all age groups, hospitalization and death among persons at high risk,
otitis media among children, and work absenteeism among adults (9–18 ). Although
influenza vaccination levels have increased substantially, further improvements in vac-
cine coverage levels are needed, particularly among persons at high risk aged <65
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years. The ACIP recommends the use of strategies to improve vaccination levels, in-
cluding the use of reminder/recall systems and standing orders programs (19,20 ).
Although influenza vaccination remains the cornerstone for the control and treat-
ment of influenza, updated information is also presented on antiviral medications be-
cause these agents are an adjunct to vaccine.
Primary Changes in the Recommendations
These recommendations include five principal changes:
• Information regarding the cost-effectiveness of influenza vaccination has been
added.
• Information regarding the influenza vaccine supply has been added.
• Information regarding neuraminidase-inhibitor antiviral drugs has been updated.
• The 2001–2002 trivalent vaccine virus strains are A/Moscow/10/99 (H3N2)-like, A/
New Caledonia/20/99 (H1N1)-like, and B/Sichuan/379/99-like strains.
• The recommended optimal time period for vaccinating individuals is October–
November.
Influenza and Its Burden
Biology of Influenza
Influenza A and B are the two types of influenza viruses that cause epidemic human
disease (21 ). Influenza A viruses are further categorized into subtypes on the basis of
two surface antigens: hemagglutinin (H) and neuraminidase (N). Influenza B viruses
are not categorized into subtypes. Since 1977, influenza A (H1N1) viruses, influenza A
(H3N2) viruses, and influenza B viruses have been in global circulation. Both influenza
A and B viruses are further separated into groups on the basis of antigenic characteris-
tics. New influenza virus variants result from frequent antigenic change (i.e., antigenic
drift) resulting from point mutations that occur during viral replication. Influenza B vi-
ruses undergo antigenic drift less rapidly than influenza A viruses.
A person’s immunity to the surface antigens, especially hemagglutinin, reduces the
likelihood of infection and severity of disease if infection occurs (22 ). Antibody against
one influenza virus type or subtype confers limited or no protection against another
influenza virus type or subtype. Furthermore, antibody to one antigenic variant of influ-
enza virus might not protect against a new antigenic variant of the same type or sub-
type (23 ). Frequent development of antigenic variants through antigenic drift is the
virologic basis for seasonal epidemics and the reason for the incorporation of one or
more new strains in each year’s influenza vaccine.
Clinical Signs and Symptoms of Influenza
Influenza viruses are spread from person-to-person primarily through the coughing
and sneezing of infected persons (21 ). The incubation period for influenza is 1–4 days,
with an average of 2 days (24 ). Persons can be infectious starting the day before symp-
toms begin through approximately 5 days after illness onset; children can be infectious
for a longer period.
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Uncomplicated influenza illness is characterized by the abrupt onset of constitutional
and respiratory signs and symptoms (e.g., fever, myalgia, headache, severe malaise,
nonproductive cough, sore throat, and rhinitis) (25 ). Respiratory illness caused by influ-
enza is difficult to distinguish from illness caused by other respiratory pathogens on the
basis of symptoms alone (see Role of Laboratory Diagnosis section). Reported sensitiv-
ity and specificity of clinical definitions for influenza-like illness that include fever and
cough have ranged from 63% to 78% and 55% to 71%, respectively, compared with viral
culture (26,27 ). Sensitivity and predictive value of clinical definitions can vary, depend-
ing on the degree of co-circulation of other respiratory pathogens and the level of influ-
enza activity (28 ).
Influenza illness typically resolves after several days for most persons, although
cough and malaise can persist for >2 weeks. In some persons, influenza can exacerbate
underlying medical conditions (e.g., pulmonary or cardiac disease), lead to secondary
bacterial pneumonia or primary influenza viral pneumonia, or occur as part of a co-
infection with other viral or bacterial pathogens (29 ). Influenza infection has also been
associated with encephalopathy, transverse myelitis, Reye syndrome, myositis, myo-
carditis, and pericarditis (29 ).
Hospitalizations and Deaths from Influenza
The risks for complications, hospitalizations, and deaths from influenza are higher
among persons aged >65 years, very young children, and persons of any age with
certain underlying health conditions than among healthy older children and younger
adults (1,30–33 ). Estimated rates of influenza-associated hospitalizations have varied
substantially by age group in studies conducted during different influenza epidemics
(Table 1).
Among children aged 0–4 years, hospitalization rates have ranged from approxi-
mately 500/100,000 population for those with high-risk conditions to 100/100,000 popu-
lation for those without high-risk conditions (34,35 ). Within the 0–4 age group,
hospitalization rates are highest among children aged 0–1 years and are comparable to
rates found among persons >65 years (36,37 ) (Table 1).
During influenza epidemics from 1969–1970 through 1994–1995, the estimated over-
all number of influenza-associated hospitalizations in the United States has ranged
from approximately 16,000 to 220,000/epidemic. An average of approximately 114,000
influenza-related excess hospitalizations occurred per year, with 57% of all hospitaliza-
tions occurring among persons aged <65 years. Since the 1968 influenza A (H3N2)
virus pandemic, the greatest numbers of influenza-associated hospitalizations have
occurred during epidemics caused by type A(H3N2) viruses, with an estimated average
of 142,000 influenza-associated hospitalizations per year (38 ).
During influenza epidemics, influenza-related deaths can result from pneumonia as
well as from exacerbations of cardiopulmonary conditions and other chronic diseases.
In studies of influenza epidemics occurring from 1972–1973 through 1994–1995, excess
deaths (i.e., the number of influenza-related deaths above a projected baseline of ex-
pected deaths) occurred during 19 of 23 influenza epidemics (39 ) (Influenza Branch,
Division of Viral and Rickettsial Diseases [DVRD], National Center for Infectious Dis-
eases [NCID], CDC, unpublished data, 1998). During those 19 influenza seasons, esti-
mated rates of influenza-associated deaths ranged from approximately 30 to >150
deaths/100,000 persons aged >65 years (Influenza Branch, DVRD, NCID, CDC, unpub-
lished data, 1998). Older adults currently account for >90% of deaths attributed to
4 MMWR April 20, 2001
pneumonia and influenza (40 ). From 1972–1973 through 1994–1995, >20,000 influenza-
associated deaths were estimated to occur during each of 11 different U.S. epidemics,
and >40,000 influenza-associated deaths were estimated for each of 6 of these 11 epi-
demics (39 ) (Influenza Branch, DVRD, NCID, CDC, unpublished data, 1998). In the United
States, pneumonia and influenza deaths might be increasing in part because the num-
ber of elderly persons is increasing (41 ).
Options for Controlling Influenza
In the United States, the main option for reducing the impact of influenza is
immunoprophylaxis with inactivated (i.e., killed virus) vaccine (see Recommendations
for the Use of Influenza Vaccine). Vaccinating persons at high risk for complications
TABLE 1. Estimated rates of influenza-associated hospitalization by age group and risk
group from selected studies.*
Hospitalizations/ Hospitalizations/
100,000 persons 100,000 persons
Study years Population Age Group at high risk not at high risk
1973–1993†§ Tennessee 0–11 mos 1,900 496–1,038¶
1973–19933§** Medicaid 1–2 yrs 800 186
3–4 yrs 320 86
5–14 yrs 92 41
1992–1997†† §§ Two Health 0–23 mos 144–187
Maintenance 2–4 yrs 0–25
Organizations 5–17 yrs 8–12
1968–1969,¶¶ *** Health 15–44 yrs 56–110 23–25
1970–1971, Maintenance 45–64 yrs 392–635 13–23
1972–1973 Organization >65 yrs 399–518 —
1969–1995††† *** National <65 yrs —§§§ 20–42§§§ ¶¶¶
Hospital >65 yrs — 125–228¶¶¶
Discharge
Data
* Rates were estimated in years and populations with low vaccination rates. Hospitalization rates would be
expected to decrease as vaccination rates increased. Vaccination can be expected to reduce influenza-related
hospitalizations by 30%–70% among elderly persons and likely by even higher percentages among younger
age groups when vaccine and circulating influenza virus strains are antigenically similar.
† Source: Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. Effect of influenza on hospitalizations,
outpatient visits, and courses of antibiotics in children. New Engl J Med 2000;342:225–31.
§ Outcomes were for acute cardiac or pulmonary conditions.
¶ The low estimate is for infants aged 6–11 months, and the high estimate is for infants aged 0–5 months.
** Source: Neuzil KM, Wright PF, Mitchel EF, Griffin MR. Burden of influenza illness in children with asthma and
other chronic medical conditions. J Pediatr 2000;137:856–64.
†† Source: Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory
disease among infants and young children. New Engl J Med 2000;342:232–9.
§§ Outcomes were for acute pulmonary conditions. Influenza-attributable hospitalization rates for children at
high risk were not included in this study.
¶¶ Source: Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J
Epidemiol 1980;112:798–811.
*** Outcomes were limited to hospitalizations in which either pneumonia or influenza was listed as the first
condition on discharge records (Simonsen) or included anywhere in the list of discharge diagnoses (Barker).
††† Source: Simonsen L, Fukuda, K, Schonberger LB, Cox NJ. Impact of influenza epidemics on hospitalizations.
J Infect Dis 2000;181:831–7.
§§§ Persons at high risk and not at high risk are combined.
¶¶¶ The low estimate is the average during influenza A(H1N1) or influenza B-predominate seasons, and the high
estimate is the average during influenza A (H3N2)-predominate seasons.
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before the influenza season each year is the most effective means of reducing the impact
of influenza. Vaccination coverage can be increased by administering vaccine to persons
during hospitalizations or routine health-care visits before the influenza season, making
special visits to physicians’ offices or clinics unnecessary. When vaccine and epidemic
strains are well-matched, achieving increased vaccination rates among persons living in
closed settings (e.g., nursing homes and other chronic-care facilities) and among staff
can reduce the risk for outbreaks by inducing herd immunity (14 ). Vaccination of health-
care workers and other persons in close contact with persons in groups at high risk can
also reduce transmission of influenza and subsequent influenza-related complications.
The use of influenza-specific antiviral drugs for chemoprophylaxis or treatment of
influenza is an important adjunct to vaccine (see Recommendations for the Use of An-
tiviral Agents for Influenza). However, antiviral medications are not a substitute for
vaccination.
Influenza Vaccine Composition
Influenza vaccine contains three strains (i.e., two type A and one type B), represent-
ing the influenza viruses likely to circulate in the United States in the upcoming winter.
The vaccine is made from highly purified, egg-grown viruses that have been made
noninfectious (i.e., inactivated) (42 ). Subvirion and purified surface-antigen prepara-
tions are available. Because the vaccine viruses are initially grown in embryonated
hens’ eggs, the vaccine might contain small amounts of residual egg protein. Influenza
vaccine distributed in the United States might also contain thimerosal, a mercury-
containing compound, as the preservative (43 ). Manufacturing processes differ by
manufacturer. Certain manufacturers might use additional compounds to inactivate
the influenza viruses, and they might use an antibiotic to prevent bacterial contamina-
tion. Package inserts should be consulted for additional information.
The trivalent influenza vaccine prepared for the 2001–2002 season will include A/
Moscow/10/99 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, and B/Sichuan/379/99-
like antigens. For the A/Moscow/10/99 (H3N2)-like antigen, manufacturers will use the
antigenically equivalent A/Panama/2007/99 (H3N2) virus; and for the B/Sichuan/379/99-
like antigen, they will use one of the antigenically equivalent viruses B/Johannesburg/
5/99, B/Victoria/504/2000, or B/Guangdong/120/2000. These viruses will be used be-
cause of their growth properties and because they are representative of currently circu-
lating A (H3N2) and B viruses.
Effectiveness of Inactivated Influenza Vaccine
The effectiveness of influenza vaccine depends primarily on the age and immuno-
competence of the vaccine recipient and the degree of similarity between the viruses in
the vaccine and those in circulation. Most vaccinated children and young adults de-
velop high postvaccination hemagglutination-inhibition antibody titers (44,45 ). These
antibody titers are protective against illness caused by strains similar to those in the
vaccine (45–47 ). When the vaccine and circulating viruses are antigenically similar,
influenza vaccine prevents influenza illness in approximately 70%–90% of healthy per-
sons aged <65 years (48 ). Vaccination of healthy adults also has resulted in decreased
work absenteeism and decreased use of health-care resources, including the use of
antibiotics, when the vaccine and circulating viruses are well-matched (10–13,49,50 ).
Other studies suggest that the use of trivalent inactivated influenza vaccine decreases
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the incidence of influenza-associated otitis media and the use of antibiotics among chil-
dren (17,18 ).
Elderly persons and persons with certain chronic diseases might develop lower
postvaccination antibody titers than healthy young adults and thus can remain suscep-
tible to influenza-related upper respiratory tract infection (51–53 ). However, among
such persons, the vaccine can be effective in preventing secondary complications and
reducing the risk for influenza-related hospitalization and death (14–16 ). Among eld-
erly persons living outside of nursing homes or similar chronic-care facilities, influenza
vaccine is 30%–70% effective in preventing hospitalization for pneumonia and influ-
enza (16,54 ). Among elderly persons residing in nursing homes, influenza vaccine is
most effective in preventing severe illness, secondary complications, and deaths.
Among this population, the vaccine can be 50%–60% effective in preventing hospital-
ization or pneumonia and 80% effective in preventing death, even though the effective-
ness in preventing influenza illness often ranges from 30% to 40% (55,56 ).
Cost-Effectiveness of Influenza Vaccine
Influenza vaccination can reduce both health-care costs and productivity losses asso-
ciated with influenza illness. Economic studies of influenza vaccination of persons aged
>65 years conducted in the United States have found overall societal cost-savings and
substantial reductions in hospitalization and death (16,54,57 ). Studies of adults aged <65
years have shown that vaccination can reduce both direct medical costs and indirect
costs from work absenteeism (9,11–13,49 ). Reductions of 34%–44% in physician visits,
32%–45% in lost work days (11,13 ), and 25% in antibiotic use have been reported (13 ).
One cost-effectiveness meta-analysis estimated a cost of approximately $60–$4,000/
illness averted among healthy persons aged 18–64 years, depending on the cost of
vaccination, the influenza attack rate, and vaccine effectiveness against influenza-like
illness (49 ). Another cost-benefit economic model estimated an average annual savings
of $13.66/person vaccinated (58 ). In the second study, 78% of all costs prevented were
costs from lost work productivity, whereas the first study did not include productivity
losses from influenza illness. Economic studies specifically evaluating the cost-effective-
ness of vaccinating persons aged 50–64 years are not available, and the number of
studies that examine the economics of routinely vaccinating children are limited
(9,59,60 ). However, in a study that included all age groups, cost-utility improved with
increasing age and among those with chronic medical conditions (9 ). Among persons
aged >65 years, vaccination resulted in a net savings per quality-adjusted-life-year
(QALY) gained and resulted in costs of $23–$256/QALY among younger age groups.
Additional studies of the relative cost-effectiveness and cost-utility of influenza vaccina-
tion among children and among adults aged <65 years are needed and should be
designed to account for year-to-year variations in influenza attack rates, illness severity,
and vaccine efficacy when evaluating the long-term costs and benefits of annual vacci-
nation.
Vaccination Coverage Levels
Among persons aged >65 years, influenza vaccination levels increased from 33% in
1989 (61 ) to 63% in 1997 and 1998 (62 ), surpassing the Healthy People 2000 goal of
60% (63 ). Although influenza vaccination coverage increased through 1997 among
black, Hispanic, and white populations, vaccination levels among blacks and Hispanics
continue to lag behind those among whites (62,64 ). In 1998, the influenza vaccination
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rate among persons aged >65 years were 66% among non-Hispanic whites, 46% among
non-Hispanic blacks, and 50% among Hispanics (62 ).
Possible reasons for the increase in influenza vaccination levels among persons
aged >65 years through 1997 include greater acceptance of preventive medical ser-
vices by practitioners, increased delivery and administration of vaccine by health-care
providers and sources other than physicians, new information regarding influenza vac-
cine effectiveness, cost-effectiveness, and safety, and the initiation of Medicare reim-
bursement for influenza vaccination in 1993 (9,15,16,55,56,65,66 ). Continued monitoring
is needed to determine if vaccination coverage among persons aged >65 years has
reached a peak or plateau. The Healthy People 2010 objective is to achieve vaccination
coverage for 90% of persons aged >65 years (67 ).
In 1997 and 1998, vaccination rate estimates among nursing home residents were
64%–82% and 83%, respectively (68,69 ). The Healthy People 2010 goal is to achieve
influenza vaccination of 90% of nursing home residents, an increase from the Healthy
People 2000 goal of 80% (63,67 ).
In 1998, the overall vaccination rate for adults aged 18–64 years with high-risk con-
ditions was 31%, far short of the Healthy People 2000 goal of 60% (62,63 ). Among
persons aged 50–64 years, 43% of those with chronic medical conditions and 29% of
those without chronic medical conditions received influenza vaccine. Only 23% of adults
younger than 50 years with high-risk conditions were vaccinated (National Immuniza-
tion Program [NIP], CDC, unpublished data, 2000).
Reported vaccination rates of children at high risk are low. One study conducted
among patients in health maintenance organizations found influenza vaccination rates
ranging from 9% to 10% among asthmatic children (70 ), and a rate of 25% was found
among children with severe-to-moderate asthma who attended an allergy and immu-
nology clinic (71 ). Increasing vaccination coverage among persons who have high-risk
conditions and are aged <65 years, including children at high risk, is the highest priority
for expanding influenza vaccine use.
Annual vaccination is recommended for health-care workers. Nonetheless, the Na-
tional Health Interview Survey found vaccination rates of only 34% and 37% among
health-care workers in the 1997 and 1998 surveys, respectively (72; NIP, CDC, unpub-
lished data, 2001). Vaccination of health-care workers has been associated with reduced
work absenteeism (10 ) and fewer deaths among nursing home patients (73,74 ).
Limited information is available regarding the use of influenza vaccine among preg-
nant women. Among women aged 18–44 years without diabetes responding to the
1999 Behavioral Risk Factor Surveillance Survey, those reporting they were pregnant
were less likely to report influenza vaccination in the past 12 months (9.6%) than those
not pregnant (15.7%). Vaccination coverage among pregnant women did not signifi-
cantly change during 1997–1999, whereas coverage among nonpregnant women in-
creased from 14.4% in 1997. Though not directly measuring influenza vaccination
among women who were past the second trimester of pregnancy during influenza sea-
son, these data indicate low compliance with the ACIP recommendations for pregnant
women (75 ). In a study of influenza vaccine acceptance by pregnant women, 71% of-
fered the vaccine chose to be vaccinated (76 ). However, a 1999 survey of obstetricians
and gynecologists determined that only 39% gave influenza vaccine to obstetric pa-
tients although 86% agree that pregnant women’s risk for influenza-related morbidity
and mortality increased in the last two trimesters (77 ).
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RECOMMENDATIONS FOR THE USE
OF INFLUENZA VACCINE
Influenza vaccine is strongly recommended for any person aged >6 months who —
because of age or underlying medical condition — is at increased risk for complications
of influenza. In addition, health-care workers and other individuals (including house-
hold members) in close contact with persons at high risk should be vaccinated to de-
crease the risk for transmitting influenza to persons at high risk. Influenza vaccine also
can be administered to any person aged >6 months to reduce the chance of becoming
infected with influenza.
Target Groups for Vaccination
Persons at Increased Risk for Complications
Vaccination is recommended for the following groups of persons who are at in-
creased risk for complications from influenza:
• persons aged >65 years;
• residents of nursing homes and other chronic-care facilities that house persons of
any age who have chronic medical conditions;
• adults and children who have chronic disorders of the pulmonary or
cardiovascular systems, including asthma;
• adults and children who have required regular medical follow-up or
hospitalization during the preceding year because of chronic metabolic diseases
(including diabetes mellitus), renal dysfunction, hemoglobinopathies, or
immunosuppression (including immunosuppression caused by medications or
by human immunodeficiency [HIV] virus);
• children and teenagers (aged 6 months–18 years) who are receiving long-term
aspirin therapy and, therefore, might be at risk for developing Reye syndrome
after influenza infection; and
• women who will be in the second or third trimester of pregnancy during the
influenza season.
Approximately 35 million persons in the United States are aged >65 years; an addi-
tional 10–13 million adults aged 50–64 years, 15–18 million adults aged 18–49 years,
and 8 million children aged 6 months–17 years have >1 medical conditions that are
associated with an increased risk of influenza-related complications (NIP, CDC, unpub-
lished data, 2000).
Persons Aged 50–64 Years
Vaccination is recommended for persons aged 50–64 years because this group has
an increased prevalence of persons with high-risk conditions. Approximately 41 mil-
lion persons in the United States are aged 50–64 years, and 10–13 million (24%–32%)
have >1 high-risk medical conditions (NIP, CDC, unpublished data, 2000). Influenza vac-
cine has been recommended for this entire age group to raise the low vaccination rates
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among persons in this age group with high-risk conditions. Age-based strategies have
been more successful in increasing vaccine coverage than patient-selection strategies
based on medical conditions. Persons aged 50–64 years without high-risk conditions
also receive benefit from vaccination in the form of decreased rates of influenza illness,
decreased work absenteeism, and decreased need for medical visits and medication,
including antibiotics (10–13 ). Further, 50 years is an age when other preventive ser-
vices begin and when routine assessment of vaccination and other preventive services
has been recommended (78,79 ).
Persons Who Can Transmit Influenza to Those at High Risk
Persons who are clinically or subclinically infected can transmit influenza virus to
persons at high risk for complications from influenza. Decreasing transmission of influ-
enza from caregivers to persons at high risk might reduce influenza-related deaths
among persons at high risk. Evidence from two studies indicates that vaccination of
health-care workers is associated with decreased deaths among nursing home patients
(73,74 ). Vaccination of health-care workers and others in close contact with persons at
high risk, including household members, is recommended. The following groups should
be vaccinated:
• physicians, nurses, and other personnel in both hospital and outpatient-care
settings, including emergency response workers;
• employees of nursing homes and chronic-care facilities who have contact with
patients or residents;
• employees of assisted living and other residences for persons in groups at high
risk;
• persons who provide home care to persons in groups at high risk; and
• household members (including children) of persons in groups at high risk.
Influenza Vaccine Supply
In 2000, difficulties with growing and processing the influenza A (H3N2) vaccine
strain and other manufacturing problems resulted in substantial delays in the distribu-
tion of the 2000–2001 influenza vaccine (80 ). In October 2000, ACIP recommended that
persons at highest risk of influenza-related complications (i.e., persons aged >65 years
and those aged <65 years with high-risk medical conditions) and health-care workers
receive vaccine first. ACIP also recommended that special efforts be made to vaccinate
all persons aged 50–64 years, beginning in December, and to continue efforts to vacci-
nate groups at high risk through December and later (81 ). The possibility of future
influenza vaccine delivery delays or vaccine shortages remains. Steps to address such
situations include identification and implementation of ways to strengthen the influ-
enza vaccine supply, to improve targeted delivery of vaccine to groups at high risk, and
to further encourage the administration of vaccine throughout the influenza season.
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Additional Information Regarding Vaccination
of Specific Populations
Pregnant Women
Influenza-associated excess deaths among pregnant women were documented dur-
ing the pandemics of 1918–1919 and 1957–1958 (82–85 ). Case reports and limited stud-
ies also suggest that pregnancy can increase the risk for serious medical complications
of influenza as a result of increases in heart rate, stroke volume, and oxygen consump-
tion; decreases in lung capacity; and changes in immunologic function (86–89 ). A study
of the impact of influenza during 17 interpandemic influenza seasons demonstrated
that the relative risk for hospitalization for selected cardiorespiratory conditions among
pregnant women enrolled in Medicaid increased from 1.4 during weeks 14–20 of gesta-
tion to 4.7 during weeks 37–42 in comparison with women who were 1–6 months post-
partum (90 ). Women in their third trimester of pregnancy were hospitalized at a rate
(i.e., 250/100,000 pregnant women) comparable with that of nonpregnant women who
had high-risk medical conditions. Using data from this study, researchers estimated
that an average of 1–2 hospitalizations could be prevented for every 1,000 pregnant
women vaccinated. Women who will be beyond the first trimester of pregnancy (>14
weeks’ gestation) during the influenza season should be vaccinated. Pregnant women
who have medical conditions that increase their risk for complications from influenza
should be vaccinated before the influenza season, regardless of the stage of pregnancy.
Because currently available influenza vaccine is an inactivated vaccine, experts con-
sider influenza vaccination safe during any stage of pregnancy. A study of influenza
vaccination of >2,000 pregnant women demonstrated no adverse fetal effects associ-
ated with influenza vaccine (91 ). However, additional data are needed to confirm the
safety of vaccination during pregnancy. Some experts prefer to administer influenza
vaccine during the second trimester to avoid a coincidental association with spontane-
ous abortion, which is common in the first trimester, and because exposures to vac-
cines traditionally have been avoided during the first trimester.
Influenza vaccine distributed in the United States contains thimerosal, a mercury-
containing compound, as a preservative. This preservative has been used in U.S. vac-
cines since the 1930s. No data or evidence exists of any harm caused by the level of
mercury exposure that might occur from influenza vaccination. Because pregnant
women are at increased risk for influenza-related complications and because a sub-
stantial safety margin has been incorporated into the health guidance values for or-
ganic mercury exposure, the benefit of influenza vaccine outweighs the potential risks
for thimerosal (92,93 ).
Persons Infected with HIV
Limited information is available regarding the frequency and severity of influenza
illness or the benefits of influenza vaccination among persons with HIV infection (94,95 ).
However, a retrospective study of young and middle-aged women enrolled in
Tennessee’s Medicaid program found that the attributable risk for cardiopulmonary
hospitalizations among women with HIV infection was higher during influenza seasons
than during the peri-influenza periods. The risk for hospitalization was higher for HIV-
infected women than for women with other well-recognized high-risk conditions, in-
cluding chronic heart and lung diseases (96 ). Another study estimated that the risk for
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influenza-related death was 9.4–14.6/10,000 persons with AIDS compared with rates of
0.09–0.10/10,000 among all persons aged 25–54 years and 6.4–7.0/10,000 among per-
sons aged >65 years (97 ). Other reports demonstrate that influenza symptoms might
be prolonged and the risk for complications from influenza increased for certain HIV-
infected persons (98,99 ).
Influenza vaccination has been shown to produce substantial antibody titers against
influenza in vaccinated HIV-infected persons who have minimal acquired immuno-
deficiency syndrome-related symptoms and high CD4+ T-lymphocyte cell counts (100–103 ).
A small, randomized, placebo-controlled trial found that influenza vaccine was highly
effective in preventing symptomatic, laboratory-confirmed influenza infection among
HIV-infected persons with a mean of 400 CD4+ T-lymphocyte cells/mm3; a limited number
of persons with CD4+ T-lymphocyte cell counts of <200 were included in that study (95 ).
Among patients who have advanced HIV disease and low CD4+ T-lymphocyte cell counts,
influenza vaccine might not induce protective antibody titers (102,103 ); a second dose of
vaccine does not improve the immune response in these persons (103,104 ).
One study found that HIV RNA levels increased transiently in one HIV-infected patient
after influenza infection (105 ). Studies have demonstrated a transient (i.e., 2–4-week)
increase in replication of HIV-1 in the plasma or peripheral blood mononuclear cells of
HIV-infected persons after vaccine administration (102,106 ). Other studies using similar
laboratory techniques have not documented a substantial increase in the replication of
HIV (107–109 ). Deterioration of CD4+ T-lymphocyte cell counts or progression of HIV
disease have not been demonstrated among HIV-infected persons after influenza vacci-
nation compared with unvaccinated persons (103,110 ). Limited information is available
concerning the effect of antiretroviral therapy on increases in HIV RNA levels after either
natural influenza infection or influenza vaccination (94,111 ). Because influenza can re-
sult in serious illness and because influenza vaccination can result in the production of
protective antibody titers, vaccination will benefit HIV-infected patients, including HIV-
infected pregnant women.
Breastfeeding Mothers
Influenza vaccine does not affect the safety of mothers who are breastfeeding or their
infants. Breastfeeding does not adversely affect the immune response and is not a con-
traindication for vaccination.
Travelers
The risk for exposure to influenza during travel depends on the time of year and
destination. In the tropics, influenza can occur throughout the year. In the temperate
regions of the Southern Hemisphere, the majority of influenza activity occurs during
April–September. In temperate climate zones of the Northern and Southern Hemi-
spheres, travelers also can be exposed to influenza during the summer, especially when
traveling as part of large organized tourist groups that include persons from areas of
the world where influenza viruses are circulating. Persons at high risk for complications
of influenza who were not vaccinated with influenza vaccine during the preceding fall
or winter should consider receiving influenza vaccine before travel if they plan to
• travel to the tropics;
• travel with large organized tourist groups at any time of year; or
• travel to the Southern Hemisphere during April–September.
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No information is available regarding the benefits of revaccinating persons before
summer travel who were already vaccinated in the preceding fall. Persons at high risk
who received the previous season’s vaccine before travel should be revaccinated with
the current vaccine in the following fall or winter. Persons aged >50 years and others at
high risk might wish to consult with their physicians before embarking on travel during
the summer to discuss the symptoms and risks for influenza and the advisability of
carrying antiviral medications for either prophylaxis or treatment of influenza.
General Population
In addition to the groups for which annual influenza vaccination is recommended,
physicians should administer influenza vaccine to any person who wishes to reduce
the likelihood of becoming ill with influenza (the vaccine can be administered to chil-
dren as young as age 6 months), depending on vaccine availability (see Vaccine Sup-
ply). Persons who provide essential community services should be considered for
vaccination to minimize disruption of essential activities during influenza outbreaks.
Students or other persons in institutional settings (e.g., those who reside in dormito-
ries) should be encouraged to receive vaccine to minimize the disruption of routine
activities during epidemics.
Persons Who Should Not Be Vaccinated
Inactivated influenza vaccine should not be administered to persons known to have
anaphylactic hypersensitivity to eggs or to other components of the influenza vaccine
without first consulting a physician (see Side Effects and Adverse Reactions). Prophy-
lactic use of antiviral agents is an option for preventing influenza among such persons.
However, persons who have a history of anaphylactic hypersensitivity to vaccine com-
ponents but who are also at high risk for complications of influenza can benefit from
vaccine after appropriate allergy evaluation and desensitization. Information regarding
vaccine components can be found in package inserts from each manufacturer.
Persons with acute febrile illness usually should not be vaccinated until their symp-
toms have abated. However, minor illnesses with or without fever do not contraindi-
cate the use of influenza vaccine, particularly among children with mild upper respiratory
tract infection or allergic rhinitis.
Timing of Annual Vaccination
The optimal time to vaccinate persons in groups at high risk is usually during
October–November. However, to avoid missed opportunities for vaccination, influenza
vaccine should be offered to persons at high risk when they are seen by health-care
providers for routine care or are hospitalized in September, provided that vaccine is
available. In addition, health-care providers should also continue to offer vaccine to
unvaccinated persons after November and throughout the influenza season even after
influenza activity has been documented in the community. In the United States, sea-
sonal influenza activity can begin to increase as early as November or December but
has not reached peak levels in the majority of recent seasons until late December
through early March (Table 2) (81,112 ). Therefore, although the timing of influenza
activity can vary by region, vaccine administered after November is likely to be benefi-
cial in most influenza seasons. Adults develop peak antibody protection against influenza
infection 2 weeks after vaccination (113,114 ).
Vol. 50 / No. RR-4 MMWR 13
Persons planning substantial organized vaccination campaigns might consider sched-
uling these events after mid-October. Although influenza vaccine generally becomes
available by September, the availability of vaccine in any location cannot be ensured
consistently in the early fall. Scheduling campaigns after mid-October will minimize the
need for cancellations because vaccine is unavailable. In facilities housing elderly per-
sons (e.g., nursing homes), vaccination before October generally should be avoided
because antibody levels in such individuals can begin to decline within a few months
after vaccination (115,116 ). (For information regarding vaccination of travelers, see
Travelers.)
Dosage
Dosage recommendations vary according to age group (Table 3). Among previously
unvaccinated children aged <9 years, two doses administered >1 months apart are
recommended for satisfactory antibody responses. If possible, the second dose should
be administered before December. Among adults, studies have indicated little or no
improvement in antibody response when a second dose is administered during the same
season (117–120 ). Even when the current influenza vaccine contains one or more of the
antigens administered in previous years, annual vaccination with the current vaccine is
necessary because immunity declines during the year following vaccination (115,116 ).
TABLE 2. Month of peak influenza activity during 19 influenza seasons — United States,
1982–2000
Month December January February March
Number (%) of years 4 (21%) 5 (26%) 7 (37%) 3 (16%)
with peak influenza activity
TABLE 3. Influenza vaccine* dosage, by age group — United States, 2001–2002 season
Number
Age group Product† Dose of doses Route§
6–35 mos Split virus only 0.25 mL 1 or 2¶ Intramuscular
3–8 yrs Split virus only 0.50 mL 1 or 2¶ Intramuscular
9–12 yrs Split virus only 0.50 mL 1 Intramuscular
>12 yrs Whole or split virus** 0.50 mL 1 Intramuscular
* Contains 15 mg each of A/New Caledonia/20/99 (H1N1)-like, A/Moscow/10/99 (H3N2)-like, and B/Sichuan/379/
99-like strains. For the A/Moscow/10/99 (H3N2)-like antigen, manufacturers will use the antigenically equiva-
lent A/Panama/2007/99 (H3N2) virus. For the B/Sichuan/379/99-like antigen, manufacturers will use one of the
antigenically equivalent viruses B/Johannesburg/5/99, B/Victoria/504/2000, or B/Guangdong/120/2000. Manu-
facturers include Aventis Pasteur, Inc. (Fluzone® split); Evans Vaccines, Ltd. (Fluvirin® purified surface antigen
vaccine); and Wyeth Lederle Laboratories (Flushield™ split). For further product information call Aventis Pas-
teur, (800) 822-2463; Evans Vaccines, (800) 200-4278; or Wyeth Lederle, (800) 358-7443.
† Because of their decreased potential for causing febrile reactions, only split-virus vaccines should be used for
children. The vaccines might be labeled as “split,” “subvirion,” or “purified-surface-antigen” vaccine. Immu-
nogenicity and side effects of split- and whole-virus vaccines are similar among adults when vaccines are
administered at the recommended dosage.
§ For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site
for infants and young children is the anterolateral aspect of the thigh.
¶ Two doses administered >1 months apart are recommended for children aged <9 years who are receiving
influenza vaccine for the first time.
** No whole virus vaccine will be distributed in the U.S. during the 2001–2002 influenza season.
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Vaccine prepared for a previous influenza season should not be administered to provide
protection for the current season.
Use of Inactivated Influenza Vaccine Among Children
Of the three influenza vaccines currently licensed in the United States, two influenza
vaccines (Flushield™, from Wyeth Laboratories, Inc., and Fluzone® split, from Aventis
Pasteur, Inc.) are approved for use among persons aged >6 months. One other influ-
enza vaccine, Fluvirin® (Evans Vaccines Ltd.), is labeled in the United States for use only
among persons aged >4 years because its efficacy among younger persons has not
been demonstrated. Providers should use influenza vaccine that has been approved for
vaccinating children aged 6 months–3 years.
Route
The intramuscular route is recommended for influenza vaccine. Adults and older
children should be vaccinated in the deltoid muscle. A needle length >1 inches can be
considered for these age groups because needles <1 inch might be of insufficient length
to penetrate muscle tissue in certain adults and older children (121 ). Infants and young
children should be vaccinated in the anterolateral aspect of the thigh (122 ).
Side Effects and Adverse Reactions
When educating patients regarding potential side effects, clinicians should empha-
size that a) inactivated influenza vaccine contains noninfectious killed viruses and can-
not cause influenza; and b) coincidental respiratory disease unrelated to influenza
vaccination can occur after vaccination.
Local Reactions
In placebo-controlled blinded studies, the most frequent side effect of vaccination is
soreness at the vaccination site (affecting 10%–64% of patients) that lasts <2 days (123–
125 ). These local reactions generally are mild and rarely interfere with the person’s
ability to conduct usual daily activities.
Systemic Reactions
Fever, malaise, myalgia, and other systemic symptoms can occur following vacci-
nation and most often affect persons who have had no prior exposure to the influenza
virus antigens in the vaccine (e.g., young children) (126,127 ). These reactions begin
6–12 hours after vaccination and can persist for 1–2 days.
Recent placebo-controlled trials demonstrate that among elderly persons and healthy
young adults, administration of split-virus influenza vaccine is not associated with higher
rates of systemic symptoms (e.g., fever, malaise, myalgia, and headache) when com-
pared with placebo injections (123,125 ).
Immediate — presumably allergic — reactions (e.g., hives, angioedema, allergic
asthma, and systemic anaphylaxis) rarely occur after influenza vaccination (128 ). These
reactions probably result from hypersensitivity to some vaccine component; most
reactions likely are caused by residual egg protein. Although current influenza vaccines
contain only a small quantity of egg protein, this protein can induce immediate hyper-
sensitivity reactions among persons who have severe egg allergy. Persons who have
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developed hives, have had swelling of the lips or tongue, or have experienced acute
respiratory distress or collapse after eating eggs should consult a physician for appropri-
ate evaluation to help determine if vaccine should be administered. Persons who have
documented immunoglobulin E (IgE)-mediated hypersensitivity to eggs — including those
who have had occupational asthma or other allergic responses to egg protein — might
also be at increased risk for allergic reactions to influenza vaccine, and consultation with
a physician should be considered. Protocols have been published for safely administer-
ing influenza vaccine to persons with egg allergies (129,130 ).
Hypersensitivity reactions to any vaccine component can occur. Although exposure
to vaccines containing thimerosal can lead to induction of hypersensitivity, most pa-
tients do not develop reactions to thimerosal when it is administered as a component
of vaccines, even when patch or intradermal tests for thimerosal indicate hyper-
sensitivity (131,132 ). When reported, hypersensitivity to thimerosal usually has con-
sisted of local, delayed-type hypersensitivity reactions (131 ).
Guillain-Barré Syndrome
The 1976 swine influenza vaccine was associated with an increased frequency of
Guillain-Barré syndrome (GBS) (133,134 ). Among persons who received the swine in-
fluenza vaccine in 1976, the rate of GBS that exceeded the background rate was <10
cases/1,000,000 persons vaccinated. Evidence for a causal relationship of GBS with
subsequent vaccines prepared from other influenza viruses is unclear. Obtaining strong
epidemiologic evidence for a possible small increase in risk is difficult for such a rare
condition as GBS, which has an annual incidence of 10–20 cases/1,000,000 adults (135 ),
and stretches the limits of epidemiologic investigation. More definitive data probably
will require the use of other methodologies (e.g., laboratory studies of the patho-
physiology of GBS).
During three of four influenza seasons studied during 1977–1991, the overall relative
risk estimates for GBS after influenza vaccination were slightly elevated but were not
statistically significant in any of these studies (136–138 ). However, in a study of the
1992–1993 and 1993–1994 seasons, the overall relative risk for GBS was 1.7 (95% con-
fidence interval = 1.0–2.8; p = 0.04) during the 6 weeks after vaccination, representing
approximately 1 additional case of GBS/1,000,000 persons vaccinated. The combined
number of GBS cases peaked 2 weeks after vaccination (139 ). Thus, investigations to
date indicate no substantial increase in GBS associated with influenza vaccines (other
than the swine influenza vaccine in 1976) and that, if influenza vaccine does pose a risk,
it is probably slightly more than one additional case per million persons vaccinated.
Cases of GBS after influenza infection have been reported, but no epidemiologic stud-
ies have documented such an association (140,141 ). Substantial evidence exists that
several infectious illnesses, most notably Campylobacter jejuni, as well as upper-
respiratory tract infections in general are associated with GBS (135,142–144 ).
Even if GBS were a true side effect of vaccination in the years after 1976, the esti-
mated risk for GBS of approximately 1 additional case/1,000,000 persons vaccinated is
substantially less than the risk for severe influenza, which could be prevented by vacci-
nation among all age groups, especially persons aged >65 years and those who have
medical indications for influenza vaccination (Table 1) (see Hospitalizations and Deaths
from Influenza). The potential benefits of influenza vaccination in preventing serious
illness, hospitalization, and death greatly outweigh the possible risks for developing
vaccine-associated GBS. The average case-fatality ratio for GBS is 6% and increases
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with age (135,145 ). No evidence indicates that the case-fatality ratio for GBS differs
among vaccinated persons and those not vaccinated.
The incidence of GBS among the general population is low, but persons with a
history of GBS have a substantially greater likelihood of subsequently developing GBS
than persons without such a history (136,146 ). Thus, the likelihood of coincidentally
developing GBS after influenza vaccination is expected to be greater among persons
with a history of GBS than among persons with no history of this syndrome. Whether
influenza vaccination specifically might increase the risk for recurrence of GBS is not
known; therefore, avoiding vaccinating persons who are not at high risk for severe
influenza complications and who are known to have developed GBS within 6 weeks
after a previous influenza vaccination is prudent. As an alternative, physicians might
consider the use of influenza antiviral chemoprophylaxis for these persons. Although
data are limited, for most persons who have a history of GBS and who are at high risk
for severe complications from influenza, the established benefits of influenza vaccina-
tion justify yearly vaccination.
Simultaneous Administration of Other Vaccines,
Including Childhood Vaccines
The target groups for influenza and pneumococcal vaccination overlap consider-
ably (147 ). For persons at high risk who have not previously been vaccinated with
pneumococcal vaccine, health-care providers should strongly consider administering
pneumococcal and influenza vaccines concurrently. Both vaccines can be administered
at the same time at different sites without increasing side effects (148,149 ). However,
influenza vaccine is administered each year, whereas pneumococcal vaccine is not. A
patient’s verbal history is acceptable for determining prior pneumococcal vaccination
status. When indicated, pneumococcal vaccine should be administered to patients who
are uncertain regarding their vaccination history (147 ). Children at high risk for
influenza-related complications can receive influenza vaccine at the same time they
receive other routine vaccinations.
Strategies for Implementing These Recommendations
in Health-Care Settings
Successful vaccination programs combine publicity and education for health-care
workers and other potential vaccine recipients, a plan for identifying persons at high
risk, use of reminder/recall systems, and efforts to remove administrative and financial
barriers that prevent persons from receiving the vaccine (19 ). Use of standing orders
programs is recommended for long-term care facilities (e.g., nursing homes and skilled
nursing facilities) under the supervision of a medical director to ensure the administra-
tion of recommended vaccinations for adults. Other settings (e.g., inpatient and outpa-
tient facilities, managed care organizations, assisted living facilities, correctional facilities,
pharmacies, adult workplaces, and home health-care agencies) are encouraged to intro-
duce standing orders programs as well (20 ). Persons for whom influenza vaccine is
recommended can be identified and vaccinated in the settings described in the following
sections.
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Outpatient Facilities Providing Ongoing Care
Staff in facilities providing ongoing medical care (e.g., physicians’ offices, public health
clinics, employee health clinics, hemodialysis centers, hospital specialty-care clinics, and
outpatient rehabilitation programs) should identify and label the medical records of pa-
tients who should receive vaccination. Vaccine should be offered during visits beginning
in September and throughout the influenza season. The offer of vaccination and its re-
ceipt or refusal should be documented in the medical record. Patients for whom vaccina-
tion is recommended who do not have regularly scheduled visits during the fall should be
reminded by mail or telephone of the need for vaccination.
Outpatient Facilities Providing Episodic or Acute Care
Acute health-care facilities (e.g., emergency rooms and walk-in clinics) should offer
vaccinations to persons for whom vaccination is recommended or provide written in-
formation regarding why, where, and how to obtain the vaccine. This written informa-
tion should be available in languages appropriate for the populations served by the
facility.
Nursing Homes and Other Residential Long-Term Care Facilities
Vaccination should be routinely provided to all residents of chronic-care facilities
with the concurrence of attending physicians. Consent for vaccination should be ob-
tained from the resident or a family member at the time of admission to the facility or
anytime afterwards. All residents should be vaccinated at one time, preceding the influ-
enza season. Residents admitted during the winter months after completion of the vac-
cination program should be vaccinated at the time of admission.
Acute-Care Hospitals
Persons of all ages (including children) with high-risk conditions and persons aged
>50 years who are hospitalized at any time during September–March should be offered
and strongly encouraged to receive influenza vaccine before they are discharged. In
one study, 39%–46% of patients hospitalized during the winter with influenza-related
diagnoses had been hospitalized during the preceding autumn (150 ). Thus, the hospi-
tal serves as a setting in which persons at increased risk for subsequent hospitalization
can be identified and vaccinated. Use of standing orders in this setting has been suc-
cessful in increasing vaccination of hospitalized persons (151 ).
Visiting Nurses and Others Providing Home Care
to Persons at High Risk
Nursing-care plans should identify patients for whom vaccination is recommended,
and vaccine should be administered in the home, if necessary. Caregivers and other
persons in the household (including children) should be referred for vaccination.
Other Facilities Providing Services to Persons Aged >50 Years
Such facilities as assisted-living facilities, retirement communities, and recreation
centers should offer unvaccinated residents and attendees vaccine on site before the
influenza season. Staff education should emphasize the need for influenza vaccine.
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Health-Care Workers
Before the influenza season, health-care facilities should offer influenza vaccinations
to all personnel, including night and weekend staff. Particular emphasis should be placed
on providing vaccinations for persons who care for members of groups at high risk.
Efforts should be made to educate health-care workers regarding the benefits of vacci-
nation and the potential health consequences of influenza illness for themselves and
their patients. Measures should be taken to provide all health-care workers convenient
access to influenza vaccine at the work site, free of charge, as part of employee health programs.
Evolving Developments Related to Influenza Vaccine
Potential New Vaccines
Intranasally administered, cold-adapted, live, attenuated, influenza virus vaccines
(LAIVs) are being used in Russia and have been under development in the United States
since the 1960s (152–156 ). The viruses in these vaccines replicate in the upper respira-
tory tract and elicit a specific protective immune response. LAIVs have been studied as
monovalent, bivalent, and trivalent formulations (155,156 ). LAIVs consist of live
viruses that induce minimal symptoms (i.e., attenuated) and that replicate poorly at
temperatures found in the lower respiratory tract (i.e., temperature-sensitive). Possible
advantages of LAIVs are their potential to induce a broad mucosal and systemic immune
response, ease of administration, and the acceptability of an intranasal route of adminis-
tration compared with injectable vaccines. In a 5-year study that compared trivalent
inactivated vaccine and bivalent LAIVs (administered by nose drops) and that used re-
lated but different vaccine strains, the two vaccines were found to be approximately
equivalent in terms of effectiveness (157 ). In a recent study of children aged 15–71
months, an intranasally administered trivalent LAIV was 93% effective in preventing
culture-positive influenza A (H3N2) and B infections, reduced otitis media among vacci-
nated children by 30%, and reduced otitis media with concomitant antibiotic use by
35% compared with unvaccinated children (158 ). In a follow-up study during the 1997–
1998 season, the trivalent LAIV was 86% effective in preventing culture-positive influ-
enza among children, despite a poor match between the vaccine’s influenza A (H3N2)
component and the predominant circulating influenza A (H3N2) virus (159 ). A study
conducted among healthy adults during the same season found a 9%–24% reduction in
febrile respiratory illnesses and 13%–28% reduction in lost work days (160 ). No study
has directly compared the efficacy or effectiveness of trivalent inactivated vaccine and
trivalent LAIV.
Potential Addition of Young Children to Groups
Recommended for Vaccination
During 1998, the ACIP formed a working group to explore issues related to the po-
tential expansion of recommendations for the use of influenza vaccine. The ACIP influ-
enza working group is considering the impact of influenza among young children as
well as the potential safety issues and logistic and economic consequences of recom-
mending routine vaccination of young healthy children.
Studies indicate that rates of hospitalization are higher among young children than
older children when influenza viruses are in circulation (34,36,37,161,162 ). The
increased rates of hospitalization are comparable with rates for other groups at high risk.
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However, the interpretation of these findings has been confounded by cocirculation of
respiratory syncytial viruses, which are a cause of serious respiratory viral illness among
children and which frequently circulate during the same time as influenza viruses (163–
165 ). Recent studies have attempted to separate the effects of respiratory syncytial
viruses and influenza viruses on rates of hospitalization among children aged <5 years
who do not have high-risk conditions (36,37 ). Both studies indicate that otherwise
healthy children aged <2 years, and possibly children aged 2–4 years, are at increased
risk for influenza-related hospitalization compared with older healthy children (Table 1).
Because very young healthy children are at increased risk for influenza-related hos-
pitalization, the ACIP is studying the benefits, risks, economic consequences and logis-
tical issues associated with routine immunization of this age group. Meanwhile, ACIP
continues to support vaccination of healthy children aged >6 months whose parents
wish to decrease their child’s risk for influenza infection, in addition to vaccinating
children with high-risk medical conditions.
RECOMMENDATIONS FOR THE USE
OF ANTIVIRAL AGENTS FOR INFLUENZA
Antiviral drugs for influenza are an adjunct to influenza vaccine for the control and
prevention of influenza. However, these agents are not a substitute for vaccination.
Four currently licensed influenza antiviral agents are available in the United States:
amantadine, rimantadine, zanamivir, and oseltamivir.
Amantadine and rimantadine are chemically related antiviral drugs with activity
against influenza A viruses but not influenza B viruses. Amantadine was approved in
1966 for prophylaxis of influenza A (H2N2) infection and was later approved in 1976 for
the treatment and prophylaxis of influenza type A virus infections among adults and
children aged >1 years. Rimantadine was approved in 1993 for treatment and prophy-
laxis of infection among adults and prophylaxis among children. Although rimantadine is
approved only for prophylaxis of infection among children, certain experts in the man-
agement of influenza consider it appropriate for treatment among children (see Ameri-
can Academy of Pediatrics, 2000 Red Book, in Additional Information Regarding Influenza
Infection Control Among Specific Populations).
Zanamivir and oseltamivir are neuraminidase inhibitors with activity against both
influenza A and B viruses. Both zanamivir and oseltamivir were approved in 1999 for
the treatment of uncomplicated influenza infections. Zanamivir is approved for treat-
ment for persons aged >7 years, and oseltamivir is approved for treatment for persons
aged >1 years. In 2000, oseltamivir was approved for prophylaxis of persons aged >13 years.
The four drugs differ in terms of their pharmacokinetics, side effects, and costs. An
overview of the indications, use, administration, and known primary side effects of
these medications is presented in the following sections. Information contained in this
report might not represent Food and Drug Administration approval or approved label-
ing for the antiviral agents described. Package inserts should be consulted for addi-
tional information.
Role of Laboratory Diagnosis
Appropriate treatment of patients with respiratory illness depends on accurate and
timely diagnosis. The early diagnosis of influenza can reduce the inappropriate use of
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antibiotics and provide the option of using antiviral therapy. However, because certain
bacterial infections can produce symptoms similar to influenza, bacterial infections should
be considered and appropriately treated if suspected. In addition, bacterial infections can
occur as a complication of influenza.
Influenza surveillance information as well as diagnostic testing can aid clinical judg-
ment and help guide treatment decisions. Influenza surveillance by state and local health
departments and CDC can provide information regarding the presence of influenza
viruses in the community. Surveillance can also identify the predominant circulating
types, subtypes, and strains of influenza.
Diagnostic tests available for influenza include viral culture, serology, rapid antigen
testing, and immunofluorescence (24 ). Sensitivity and specificity of any test for influ-
enza might vary by the laboratory that performs the test and by the type of test used. As
with any diagnostic test, results should be evaluated in the context of other clinical
information available to the physician.
Several commercial rapid diagnostic tests are available that can be used by labora-
tories in outpatient settings to detect influenza viruses within 30 minutes (24,166 ). These
rapid tests differ in the types of influenza virus they can detect and whether or not they
can distinguish between influenza types. Different tests can detect a) only influenza A
viruses; b) both influenza A and B viruses but not distinguish between the two types, or
c) both influenza A and B and distinguish between the two. Sensitivity and specificity of
rapid tests are lower than for viral culture and vary by test. In addition, the types of
specimens acceptable for use (i.e., throat swab, nasal wash, or nasal swab) also vary.
Package inserts and the laboratory performing the test should be consulted for more
details.
Despite the availability of rapid diagnostic tests, the collection of clinical specimens
for viral culture is critical, because only culture isolates can provide specific informa-
tion regarding circulating influenza subtypes and strains. This information is needed to
compare current circulating influenza strains with vaccine strains, to guide decisions
regarding influenza treatment and prophylaxis, and to formulate vaccine for the com-
ing year. Virus isolates also are needed to monitor the emergence of antiviral resis-
tance and the emergence of novel influenza A subtypes that might pose a pandemic
threat.
Indications for Use
Treatment
When administered within 2 days of illness onset to otherwise healthy adults, aman-
tadine and rimantadine can reduce the duration of uncomplicated influenza A illness,
and zanamivir and oseltamivir can reduce the duration of uncomplicated influenza A
and B illness by approximately 1 day (49,167–180 ). More clinical data are available
concerning the effectiveness of zanamivir and oseltamivir for treatment of influenza A
infection than for treatment of influenza B infection (169,174–179,181–184 ). However,
in vitro data (185–190 ), studies of treatment among mice and ferrets (186,187,191,192 ),
and clinical studies have documented that zanamivir and oseltamivir have activity
against influenza B viruses (173,177–179,183,184 ).
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None of the four antiviral agents has been demonstrated to be effective in preventing
serious influenza-related complications (e.g., bacterial or viral pneumonia or exacerba-
tion of chronic diseases). Evidence for the effectiveness of these four antiviral drugs is
based principally on studies of patients with uncomplicated influenza (193 ). Data are
limited and inconclusive concerning the effectiveness of amantadine, rimantadine,
zanamivir, and oseltamivir for treatment of influenza among persons at high risk for
serious complications of influenza (167,169,170,172,173,180,194–197 ). Fewer studies
of the efficacy of influenza antivirals have been conducted among pediatric popula-
tions compared with adults (167,170,176,177,196,198,199 ). One study of oseltamivir
treatment documented a decreased incidence of otitis media among children (177 ).
To reduce the emergence of antiviral drug-resistant viruses, amantadine or
rimantadine therapy for persons with influenza-like illness should be discontinued as
soon as clinically warranted, generally after 3–5 days of treatment or within 24–48 hours
after the disappearance of signs and symptoms. The recommended duration of treat-
ment with either zanamivir or oseltamivir is 5 days.
Prophylaxis
Chemoprophylactic drugs are not a substitute for vaccination, although they are criti-
cal adjuncts in the prevention and control of influenza. Both amantadine and rimantadine
are indicated for the prophylaxis of influenza A infection, but are not effective against
influenza B. Both drugs are approximately 70%–90% effective in preventing illness from
influenza A infection (49,167,196 ). When used as prophylaxis, these antiviral agents can
prevent illness while permitting subclinical infection and the development of protective
antibody against circulating influenza viruses. Therefore, certain persons who take these
drugs will develop protective immune responses to circulating influenza viruses. Aman-
tadine and rimantadine do not interfere with the antibody response to the vaccine (167 ).
Both drugs have been studied extensively among nursing home populations as a compo-
nent of influenza outbreak control programs, which can limit the spread of influenza
within chronic care institutions (167,195,200–202 ).
Among the neuraminidase inhibitor antivirals, zanamivir and oseltamivir, only
oseltamivir has been approved for prophylaxis, but community studies of healthy adults
indicate that both drugs are similarly effective in preventing febrile, laboratory-
confirmed influenza illness (efficacy: zanamivir, 84%; oseltamivir, 82%) (203,204 ). Both
antiviral agents have also been reported to prevent influenza illness among persons
given chemoprophylaxis after a household member was diagnosed with influenza
(183,205 ). Experience with prophylactic use of these agents in institutional settings or
among patients with chronic medical conditions is limited (179,206–211 ). One 6-week
study of oseltamivir prophylaxis among nursing home residents found a 92% reduc-
tion in influenza illness (179,212 ). Use of zanamivir has not been reported to impair the
immunologic response to influenza vaccine (178,213 ). Data are not available on the
efficacy of any of the four antiviral agents in preventing influenza among severely im-
mune compromised persons.
When determining the timing and duration for administering influenza antiviral
medications for prophylaxis, factors related to cost, compliance, and potential side
effects should be considered. To be maximally effective as prophylaxis, the drug must be
taken each day for the duration of influenza activity in the community. However, to be
most cost-effective, one study of amantadine or rimantadine prophylaxis reported that
the drugs should be taken only during the period of peak influenza activity in a community
(214 ).
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Persons at High Risk Who Are Vaccinated After Influenza Activity Has Begun. Per-
sons at high risk for complications of influenza still can be vaccinated after an outbreak
of influenza has begun in a community. However, the development of antibodies in
adults after vaccination can take as long as 2 weeks (118,119 ). When influenza vaccine
is given while influenza viruses are circulating, chemoprophylaxis should be consid-
ered for persons at high risk during the time from vaccination until immunity has devel-
oped. Children who receive influenza vaccine for the first time can require as long as 6
weeks of prophylaxis (i.e., prophylaxis for 4 weeks after the first dose of vaccine and an
additional 2 weeks of prophylaxis after the second dose).
Persons Who Provide Care to Those at High Risk. To reduce the spread of virus to
persons at high risk during community or institutional outbreaks, chemoprophylaxis
during peak influenza activity can be considered for unvaccinated persons who have
frequent contact with persons at high risk. Persons with frequent contact include em-
ployees of hospitals, clinics, and chronic-care facilities, household members, visiting
nurses, and volunteer workers. If an outbreak is caused by a variant strain of influenza
that might not be controlled by the vaccine, chemoprophylaxis should be considered
for all such persons, regardless of their vaccination status.
Persons Who Have Immune Deficiency. Chemoprophylaxis can be considered for
persons at high risk who are expected to have an inadequate antibody response to
influenza vaccine. This category includes persons infected with HIV, especially those
with advanced HIV disease. No published data are available concerning possible effi-
cacy of chemoprophylaxis among persons with HIV infection or interactions with other
drugs used to manage HIV infection. Such patients should be monitored closely if
chemoprophylaxis is administered.
Other Persons. Chemoprophylaxis throughout the influenza season or during peak
influenza activity might be appropriate for persons at high risk who should not be vac-
cinated. Chemoprophylaxis can also be offered to persons who wish to avoid influenza
illness. Health-care providers and patients should make this decision on an individual
basis.
Control of Influenza Outbreaks in Institutions
The use of antiviral drugs for treatment and prophylaxis of influenza is an important
component of institutional outbreak control. In addition to the use of antiviral medica-
tions, other outbreak control measures include instituting droplet precautions and
establishing cohorts of patients with confirmed or suspected influenza, re-offering influ-
enza vaccinations to unvaccinated staff and patients, restricting staff movement
between wards or buildings, and restricting contact between ill staff or visitors and
patients (215–217 ). (For additional information regarding outbreak control in specific
settings, refer to additional references in Additional Information Regarding Influenza
Infection Control Among Specific Populations.)
Most published reports on the use of antiviral agents to control institutional influenza
outbreaks are based on studies of influenza A outbreaks among nursing home popula-
tions where amantadine or rimantadine were used (167,195,200–202 ). Less information
is available concerning the use of oseltamivir in influenza A or B institutional outbreaks
(210,212 ). When confirmed or suspected outbreaks of influenza occur in institutions that
house persons at high risk, chemoprophylaxis should be started as early as possible to
reduce the spread of the virus. In these situations, having preapproved orders from
physicians or plans to obtain orders for antiviral medications on short notice is extremely
useful.
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When institutional outbreaks occur, chemoprophylaxis should be administered to all
residents — regardless of whether they received influenza vaccinations during the pre-
vious fall — and should continue for >2 weeks or until approximately 1 week after the end
of the outbreak. The dosage for each resident should be determined individually. Chemo-
prophylaxis also can be offered to unvaccinated staff who provide care to persons at
high risk. Prophylaxis should be considered for all employees, regardless of their vacci-
nation status, if the outbreak is caused by a variant strain of influenza that is not well-
matched by the vaccine.
In addition to nursing homes, chemoprophylaxis also can be considered for control-
ling influenza outbreaks in other closed or semiclosed settings (e.g., dormitories or
other settings where persons live in close proximity). For example, chemoprophylaxis
with rimantadine has been used successfully to control an influenza A outbreak aboard
a large cruise ship (218 ).
To limit the potential transmission of drug-resistant virus during institutional out-
breaks, whether in chronic or acute-care settings or other closed settings, measures
should be taken to reduce contact as much as possible between persons taking anti-viral
drugs for treatment and other persons, including those taking chemoprophylaxis (see
Antiviral Drug-Resistant Strains of Influenza).
Dosage
Dosage recommendations vary by age group and medical conditions (Table 4).
Children
Amantadine. The use of amantadine among children aged <1 year has not been
adequately evaluated. The Food and Drug Administration-approved dosage for chil-
dren aged 1–9 years for treatment and prophylaxis is 4.4–8.8 mg/kg/day, not to exceed
150 mg/day. Although further studies are needed to determine the optimal dosage for
children aged 1–9 years, physicians should consider prescribing only 5 mg/kg/day (not
to exceed 150 mg/day) to reduce the risk for toxicity. The approved dosage for children
aged >10 years is 200 mg/day (100 mg twice a day); however, for children weighing <40
kg, prescribing 5 mg/kg/day, regardless of age, is advisable (219 ).
Rimantadine. Rimantadine is approved for prophylaxis among children aged >1
years and for treatment in children aged >13 years. Although rimantadine is approved
only for prophylaxis of infection among children, certain experts in the management of
influenza consider it appropriate for treatment among children (see American Academy
of Pediatrics, 2000 Red Book, in Additional Information Regarding Influenza Infection
Control Among Specific Populations). The use of rimantadine among children aged <1
year has not been adequately evaluated. Rimantadine should be administered in one or
two divided doses at a dosage of 5 mg/kg/day, not to exceed 150 mg/day for children
aged 1–9 years. The approved dosage for children aged >10 years is 200 mg/day (100
mg twice a day); however, for children weighing <40 kg, prescribing 5 mg/kg/day, regard-
less of age, is recommended (220 ).
Zanamivir. Zanamivir is not approved for use among children aged <7 years. The
recommended dosage of zanamivir for treatment of influenza among persons aged >7
years is two inhalations (one 5-mg blister per inhalation for a total dose of 10 mg) twice
daily (approximately 12 hours apart) (178 ).
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TABLE 4. Recommended daily dosage of influenza antiviral medications for treatment
and prophylaxis
Age Groups
Antiviral agent 1–6 yrs 7–9 yrs 10–12 yrs 13–64 yrs >65 yrs
Amantadine*
Treatment 5mg/kg/day 5mg/kg/day 100 mg twice 100 mg twice <100 mg/day
up to 150 mg up to 150 mg  daily§  daily§
in two divided in two divided
doses† doses†
Prophylaxis 5mg/kg/day 5mg/kg/day 100 mg twice 100 mg twice <100 mg/day
up to 150 mg up to 150 mg daily§ daily§
in two divided in two divided
doses†    doses†
Rimantadine¶
Treatment** NA†† NA NA 100 mg twice 100 or 200§§
daily§  mg/day
Prophylaxis 5mg/kg/day 5mg/kg/day 100 mg twice 100 mg twice 100 or 200§§
up to 150 mg up to 150 mg  daily§ daily§ mg/day
in two divided in two divided
 doses†  doses†
Zanamivir¶¶ ***
Treatment NA 10 mg twice 10 mg twice 10 mg twice 10 mg twice
 daily daily  daily  daily
Oseltamivir
Treatment††† Dose varies Dose varies Dose varies 75 mg twice 75 mg twice
by child’s by child’s by child’s daily daily
weight§§§  weight§§§  weight§§§
Prophylaxis NA NA NA 75 mg/day 75 mg/day
NOTE: Amantadine manufacturers include Endo Pharmaceuticals (Symmetrel,® tablet and syrup); Geneva Phar-
maceuticals and Rosemont (Amantadine HCL, capsule); and Alpharma, Copley Pharmaceutical, HiTech
Pharma, Mikart, Morton Grove, and Pharmaceutical Associates (Amantadine HCL, syrup). Rimantadine is
manufactured by Forest Laboratories (Flumadine,® tablet and syrup). Zanamivir is manufactured by Glaxo
Wellcome (Relenza,® inhaled powder). Oseltamivir is manufactured by Hoffman-LaRoche, Inc. (Tamiflu,®
tablet and suspension).
* The drug package insert should be consulted for dosage recommendations for administering amantadine to
persons with creatinine clearance <50 mL/min/1.73m2.
† 5 mg/kg of amantadine or rimantadine syrup = 1 tsp/22 lbs.
§ Children aged >10 years who weigh <40 kg should be administered amantadine or rimantadine at a dosage
of 5 mg/kg/day.
¶ A reduction in dosage to 100 mg/day of rimantadine is recommended for persons who have severe hepatic
dysfunction or those with creatinine clearance <10 mL/min. Other persons with less severe hepatic or renal
dysfunction taking 100 mg/day of rimantadine should be observed closely, and the dosage should be re-
duced or the drug discontinued, if necessary.
** Only approved for treatment among adults.
†† Not applicable.
§§ Elderly residents of nursing-homes should be administered only 100 mg/day of rimantadine. A reduction in
dosage to 100 mg/day should be considered for all persons aged >65 years if they experience side effects
when taking 200 mg/day.
¶¶ Zanamivir is administered via inhalation by using a plastic device included in the package with the medica-
tion. Patients will benefit from instruction and demonstration of correct use of the device.
*** Zanamivir is not approved for prophylaxis.
††† A reduction in the dose of oseltamivir is recommended for persons with creatinine clearance <30 mL/min.
§§§ The dose recommendation for children who weigh <15 kg is 30 mg twice a day; for children weighing >15–
23 kg, the dose is 45 mg twice a day; for children weighting >23–40 kg, the dose is 60 mg twice a day; and for
children weighing >40 kg, the dose is 75 mg twice a day.
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Oseltamivir. Oseltamivir is not approved for use among persons aged <1 year. Rec-
ommended treatment doses for children vary by the weight of the child: the dose rec-
ommendation for children who weigh <15 kg is 30 mg twice a day; for children weighing
>15–23 kg, the dose is 45 mg twice a day; for those weighing >23–40 kg, the dose is 60
mg twice a day; and for children weighing >40 kg, the dose is 75 mg twice a day. The
treatment dosage for persons >13 years is 75 mg twice daily. For children >13 years, the
recommended dose for prophylaxis is 75 mg once a day (179 ).
Persons Aged >65 Years
Amantadine. The daily dose of amantadine for persons aged >65 years should not
exceed 100 mg for prophylaxis or treatment, because renal function declines with
increasing age. For certain elderly persons, the dose should be further reduced.
Rimantadine. Among elderly persons, the incidence and severity of central nervous
system (CNS) side effects are substantially lower among those taking rimantadine at a
dosage of 100 mg/day than among those taking amantadine at dosages adjusted for
estimated renal clearance (221 ). However, chronically ill elderly persons have had a
higher incidence of CNS and gastrointestinal symptoms and serum concentrations two
to four times higher than among healthy, younger persons when rimantadine has been
administered at a dosage of 200 mg/day (167 ).
For elderly nursing home residents, the dosage of rimantadine should be reduced
to 100 mg/day for prophylaxis or treatment. For other elderly persons, further studies
are needed to determine the optimal dosage. However, a reduction in dosage to 100
mg/day should be considered for all persons aged >65 years who experience side
effects when taking a dosage of 200 mg/day.
Zanamivir and Oseltamivir. No reduction in dosage is recommended on the basis of
age alone.
Persons with Impaired Renal Function
Amantadine. A reduction in dosage is recommended for patients with creatinine
clearance <50 mL/min/1.73m2. Guidelines for amantadine dosage on the basis of crea-
tinine clearance are found in the package insert. Because recommended dosages on
the basis of creatinine clearance might provide only an approximation of the optimal
dose for a given patient, such persons should be observed carefully for adverse reac-
tions. If necessary, further reduction in the dose or discontinuation of the drug might be
indicated because of side effects. Hemodialysis contributes minimally to amantadine
clearance (222 ).
Rimantadine. A reduction in dosage to 100 mg/day is recommended for persons
with creatinine clearance <10 mL/min. Because of the potential for accumulation of
rimantadine and its metabolites, patients with any degree of renal insufficiency, includ-
ing elderly persons, should be monitored for adverse effects, and either the dosage
should be reduced or the drug should be discontinued, if necessary. Hemodialysis
contributes minimally to drug clearance (223 ).
Zanamivir. Limited data are available regarding the safety and efficacy of zanamivir
for patients with impaired renal function. Among patients with renal failure who were
administered a single intravenous dose of zanamivir, decreases in renal clearance,
increases in half-life, and increased systemic exposure to zanamivir were observed
(178,224 ). However, a small number of healthy volunteers who were administered high
doses of intravenous zanamivir tolerated systemic levels of zanamivir that were much
26 MMWR April 20, 2001
higher than those resulting from administration of zanamivir by oral inhalation at the
recommended dose (225,226 ). On the basis of these considerations, the manufacturer
recommends no dose adjustment for inhaled zanamivir for a 5-day course of treatment
for patients with either mild-to-moderate or severe impairment in renal function (178 ).
Oseltamivir. Serum concentrations of oseltamivir carboxylate (GS4071), the active
metabolite of oseltamivir, increase with declining renal function (182,179 ). For patients
with creatinine clearance of 10–30 mL/min (179 ), a reduction of the treatment dose of
oseltamivir to 75 mg once daily and in the prophylaxis dose to 75 mg every other day is
recommended. No treatment or prophylaxis dosing recommendations are available
for patients undergoing routine renal dialysis treatment.
Persons with Liver Disease
Amantadine. No increase in adverse reactions to amantadine has been observed
among persons with liver disease. Rare instances of reversible elevation of liver
enzymes among patients receiving amantadine have been reported, although a specific
relationship between the drug and such changes has not been established (227 ).
Rimantadine. A reduction in dosage to 100 mg/day is recommended for persons
with severe hepatic dysfunction.
Zanamivir and Oseltamivir. Neither of these medications has been studied among
persons with hepatic dysfunction.
Persons with Seizure Disorders
Amantadine. An increased incidence of seizures has been reported among patients
with a history of seizure disorders who have received amantadine (228 ). Patients with
seizure disorders should be observed closely for possible increased seizure activity
when taking amantadine.
Rimantadine. Seizures (or seizure-like activity) have been reported among persons
with a history of seizures who were not receiving anticonvulsant medication while tak-
ing rimantadine (229 ). The extent to which rimantadine might increase the incidence
of seizures among persons with seizure disorders has not been adequately evaluated.
Zanamivir and Oseltamivir. Seizure events have been reported during postmarketing
use of zanamivir and oseltamivir, although no epidemiologic studies have reported any
increased risk for seizures with either zanamivir or oseltamivir use.
Route
Amantadine, rimantadine, and oseltamivir are administered orally. Amantadine and
rimantadine are available in tablet or syrup form, and oseltamivir is available in cap-
sule or oral suspension form (178,179 ). Zanamivir is available as a dry powder that is
self-administered via oral inhalation by using a plastic device included in the package
with the medication. Patients will benefit from instruction and demonstration of correct
use of this device (178 ).
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Pharmacokinetics
Amantadine
Approximately 90% of amantadine is excreted unchanged in the urine by glomerular
filtration and tubular secretion (200,230–233 ). Thus, renal clearance of amantadine is
reduced substantially among persons with renal insufficiency, and dosages might need
to be decreased (see Dosage) (Table 4).
Rimantadine
Approximately 75% of rimantadine is metabolized by the liver (196 ). The safety and
pharmacokinetics of rimantadine among persons with liver disease have been evalu-
ated only after single-dose administration (196,234 ). In a study of persons with chronic
liver disease (most with stabilized cirrhosis), no alterations in liver function were ob-
served after a single dose (175,217 ). However, for persons with severe liver dysfunc-
tion, the apparent clearance of rimantadine was 50% lower than that reported for persons
without liver disease (220 ).
Rimantadine and its metabolites are excreted by the kidneys. The safety and phar-
macokinetics of rimantadine among patients with renal insufficiency have been evalu-
ated only after single-dose administration (196,223 ). Further studies are needed to
determine multiple-dose pharmacokinetics and the most appropriate dosages for pa-
tients with renal insufficiency. In a single-dose study of patients with anuric renal fail-
ure, the apparent clearance of rimantadine was approximately 40% lower, and the
elimination half-life was approximately 1.6-fold greater than that among healthy per-
sons of the same age (223 ). Hemodialysis did not contribute to drug clearance. In stud-
ies of persons with less severe renal disease, drug clearance was also reduced, and
plasma concentrations were higher than those among control patients without renal
disease who were the same weight, age, and sex (220,235 ).
Zanamivir
In studies of healthy volunteers, approximately 7%–21% of the orally inhaled
zanamivir dose reached the lungs, and 70%–87% was deposited in the oropharynx
(236,237 ). Approximately 4%–17% of the total amount of orally inhaled zanamivir is
systemically absorbed. Systemically absorbed zanamivir has a half-life of 2.5–5.1 hours
and is excreted unchanged in the urine. Unabsorbed drug is excreted in the feces
(178,226 ).
Oseltamivir
Approximately 80% of orally administered oseltamivir is absorbed systemically
(182 ). Absorbed oseltamivir is metabolized to oseltamivir carboxylate, the active
neuraminidase inhibitor, primarily by hepatic esterases. Oseltamivir carboxylate has a
half-life of 6–10 hours and is excreted in the urine by glomerular filtration and tubular
secretion via the anionic pathway (179,238 ). Unmetabolized oseltamivir also is excreted
in the urine by glomerular filtration and tubular secretion (238 ).
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Side Effects and Adverse Reactions
When considering the use of influenza antiviral medications (i.e., choice of antiviral
drug, dose, and duration of therapy), clinicians must consider the patient’s age, weight,
and renal function (Table 4); presence of other medical conditions; indications for use
(i.e., prophylaxis or therapy); and the potential for interaction with other medications.
Amantadine and Rimantadine
Both amantadine and rimantadine can cause CNS and gastrointestinal side effects
when administered to young, healthy adults at equivalent dosages of 200 mg/day. How-
ever, incidence of CNS side effects (e.g., nervousness, anxiety, difficulty concentrating,
and lightheadedness) is higher among persons taking amantadine than among those
taking rimantadine (239 ). In a 6-week study of prophylaxis among healthy adults,
approximately 6% of participants taking rimantadine at a dosage of 200 mg/day experi-
enced >1 CNS symptoms, compared with approximately 13% of those taking the same
dosage of amantadine and 4% of those taking placebo (239 ). A study of elderly per-
sons also demonstrated fewer CNS side effects associated with rimantadine compared
with amantadine (221 ). Gastrointestinal side effects (e.g., nausea and anorexia) occur
in approximately 1%–3% of persons taking either drug, compared with 1% of persons
receiving the placebo (239 ).
Side effects associated with amantadine and rimantadine are usually mild and cease
soon after discontinuing the drug. Side effects can diminish or disappear after the first
week, despite continued drug ingestion. However, serious side effects have been
observed (e.g., marked behavioral changes, delirium, hallucinations, agitation, and sei-
zures) (228 ). These more severe side effects have been associated with high plasma
drug concentrations and have been observed most often among persons who have
renal insufficiency, seizure disorders, or certain psychiatric disorders and among eld-
erly persons who have been taking amantadine as prophylaxis at a dosage of 200 mg/
day (200 ). Clinical observations and studies have indicated that lowering the dosage of
amantadine among these persons reduces the incidence and severity of such side
effects (Table 4). In acute overdosage of amantadine, CNS, renal, respiratory, and car-
diac toxicity, including arrhythmias, have been reported (219 ). Because rimantadine has
been marketed for a shorter period than amantadine, its safety among certain patient
populations (e.g. chronically ill and elderly persons) has been evaluated less frequently.
Zanamivir
In a study of zanamivir treatment of influenza-like illness among persons with asthma
or chronic obstructive pulmonary disease where study medication was administered
after the use of a 2-agonist, 13% of patients receiving zanamivir and 14% of patients
who received placebo (inhaled powdered lactose vehicle) experienced a >20% decline
in forced expiratory volume in 1 second (FEV1) after treatment (178,180 ). However, in
a phase I study of persons with mild or moderate asthma who did not have influenza-
like illness, 1 of 13 patients experienced bronchospasm following administration of
zanamivir (178 ). In addition, during postmarketing surveillance, cases of respiratory
function deterioration following inhalation of zanamivir have been reported. Certain
patients had underlying airways disease (e.g., asthma or chronic obstructive pulmo-
nary disease). Because of the risk for serious adverse events and because the efficacy
has not been demonstrated in this population, zanamivir is generally not recommended
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for treatment for patients with underlying airway disease (178 ). If physicians decide to
prescribe zanamivir to patients with underlying chronic respiratory disease after care-
fully considering potential risks and benefits, the drug should be used with caution
under conditions of proper monitoring and supportive care, including the availability
of short-acting bronchodilators (193 ). Patients with asthma or chronic obstructive pul-
monary disease who use zanamivir are advised to a) have a fast-acting inhaled bron-
chodilator available when inhaling zanamivir and b) stop using zanamivir and contact
their physician if they develop difficulty breathing (178 ). No clear evidence is available
regarding the safety or efficacy of zanamivir for persons with underlying respiratory or
cardiac disease or for persons with complications of acute influenza (193 ).
In clinical treatment studies of persons with uncomplicated influenza, the frequen-
cies of adverse events were similar for persons receiving inhaled zanamivir and those
receiving placebo (i.e., inhaled lactose vehicle alone) (168–173,178,236 ). The most com-
mon adverse events reported by both groups were diarrhea; nausea; sinusitis; nasal
signs and symptoms; bronchitis; cough; headache; dizziness; and ear, nose, and throat
infections (150,151,153,154,191 ). Each of these symptoms was reported by <5% of
persons in the clinical treatment studies combined (178 ).
Oseltamivir
Nausea and vomiting were reported more frequently among adults receiving
oseltamivir for treatment (nausea without vomiting, approximately 10%; vomiting, ap-
proximately 9%) than among persons receiving placebo (nausea without vomiting,
approximately 6%; vomiting, approximately 3%) (174,175,179,240 ). Among children
treated with oseltamivir, 14.3% had vomiting compared with 8.5% of placebo recipi-
ents. Overall, 1% discontinued the drug secondary to this side effect (177 ), whereas a
limited number of adults enrolled in clinical treatment trials of oseltamivir discontin-
ued treatment because of these symptoms (179 ). Similar types and rates of adverse
events were found in studies of oseltamivir prophylaxis (179 ). Nausea and vomiting
might be less severe if oseltamivir is taken with food (179,240 ).
Use During Pregnancy
No clinical studies have been conducted regarding the safety or efficacy of amanta-
dine, rimantadine, zanamivir, or oseltamivir for pregnant women; only two cases of
amantadine use for severe influenza illness during the third trimester have been re-
ported (89,241 ). However, both amantadine and rimantadine have been demonstrated
in animal studies to be teratogenic and embryotoxic when administered at very high
doses (219,220 ). Because of the unknown effects of influenza antiviral drugs on preg-
nant women and their fetuses, these four drugs should be used during pregnancy only
if the potential benefit justifies the potential risk to the embryo or fetus (see package
inserts [178,179,219,220 ]).
Drug Interactions
Careful observation is advised when amantadine is administered concurrently with
drugs that affect CNS, especially CNS stimulants. Concomitant administration of anti-
histamines or anticholinergic drugs can increase the incidence of adverse CNS reac-
tions (167 ). No clinically significant interactions between rimantadine and other drugs
have been identified.
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Clinical data are limited regarding drug interactions with zanamivir. However, no
known drug interactions have been reported, and no clinically important drug interac-
tions have been predicted on the basis of in vitro data and data from studies of rats
(178,242 ).
Limited clinical data are available regarding drug interactions with oseltamivir. Be-
cause oseltamivir and oseltamivir carboxylate are excreted in the urine by glomerular
filtration and tubular secretion via the anionic pathway, a potential exists for interaction
with other agents excreted by this pathway. For example, coadministration of
oseltamivir and probenecid resulted in reduced clearance of oseltamivir carboxylate by
approximately 50% and a corresponding approximate twofold increase in the plasma
levels of oseltamivir carboxylate (179,238 ).
No published data are available concerning the safety or efficacy of using combina-
tions of any of these four influenza antiviral drugs. For more detailed information con-
cerning potential drug interactions for any of these influenza antiviral drugs, package
inserts should be consulted.
Antiviral Drug-Resistant Strains of Influenza
Amantadine-resistant viruses are cross-resistant to rimantadine and vice versa (243 ).
Drug-resistant viruses can appear in approximately one third of patients when either
amantadine or rimantadine is used for therapy (199,244 ). During the course of amanta-
dine or rimantadine therapy, resistant influenza strains can replace sensitive strains
within 2–3 days of starting therapy (244,245 ). Resistant viruses have been isolated
from persons who live at home or in an institution where other residents are taking or
have recently taken amantadine or rimantadine as therapy (246,247 ); however, the
frequency with which resistant viruses are transmitted and their impact on efforts to
control influenza are unknown. Amantadine- and rimantadine-resistant viruses are not
more virulent or transmissible than sensitive viruses (248 ). The screening of epidemic
strains of influenza A has rarely detected amantadine- and rimantadine-resistant vi-
ruses (244,249,250 ).
Persons who have influenza A infection and who are treated with either amantadine
or rimantadine can shed sensitive viruses early in the course of treatment and later
shed drug-resistant viruses, especially after 5–7 days of therapy (199 ). Such persons
can benefit from therapy even when resistant viruses emerge.
Resistance to zanamivir and oseltamivir can be induced in influenza A and B viruses
in vitro (251–258 ), but induction of resistance requires several passages in cell culture.
By contrast, resistance to amantadine and rimantadine in vitro can be induced with
fewer passages in cell culture (259,260 ). Development of viral resistance to zanamivir
and oseltamivir during treatment has been identified but does not appear to be fre-
quent (179,261–264 ). In clinical treatment studies using oseltamivir, 1.3% of posttreat-
ment isolates from patients aged >13 years and 8.6% among patients aged 1–12 years
had decreased susceptibility to oseltamivir (179 ). No isolates with reduced susceptibil-
ity to zanamivir have been reported from clinical trials, although the number of post-
treatment isolates tested is limited (265 ), and the risk for emergence of zanamivir
resistant isolates cannot be quantified (178 ). Only one clinical isolate with reduced
susceptibility to zanamivir, obtained from an immunocompromised child on prolonged
therapy, has been reported (262 ). Currently available diagnostic tests are not optimal
for detecting clinical resistance, and better tests as well as more testing are needed
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before firm conclusions can be reached (265 ). Postmarketing surveillance for neuramini-
dase inhibitor-resistant influenza viruses is being conducted.
SOURCES OF INFORMATION REGARDING INFLUENZA
AND ITS SURVEILLANCE
Information regarding influenza surveillance is available through the CDC Voice
Information System (influenza update) at (888) 232-3228; CDC Fax Information Service
at (888) 232-3299; or website for the Influenza Branch, DVRD, NCID, CDC at <http://
www.cdc.gov/ncidod/diseases/flu/weekly.htm>. During October–May, the information
is updated at least every other week. In addition, periodic updates regarding influenza
are published in the weekly MMWR. State and local health departments should be
consulted regarding availability of influenza vaccine, access to vaccination programs,
information regarding state or local influenza activity, and for reporting influenza out-
breaks and receiving advice regarding outbreak control.
ADDITIONAL INFORMATION REGARDING INFLUENZA
INFECTION CONTROL AMONG SPECIFIC POPULATIONS
Each year, the ACIP provides general, annually updated information regarding the
control and prevention of influenza. Other documents on the control and prevention of
influenza among specific populations (e.g., immunocompromised persons, health-care
workers, hospitals, and travelers) are also available in the following publications:
• Garner JS. Hospital Infection Control Practices Advisory Committee. Guideline
for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996;17:
53–80.
• Tablan OC, Anderson LJ, Arden NH, et al., Hospital Infection Control Practices
Advisory Committee. Guideline for prevention of nosocomial pneumonia. Infect
Control Hosp Epidemiol 1994;15:587–627.
• Bolyard EA, Tablan OC, Williams WW, et al., Hospital Infection Control Practices
Advisory Committee. Guideline for infection control in health care personnel. Am
J Infect Control 1998;26:289–354.
• Bradley SF, The Long-Term–Care Committee of the Society for Healthcare
Epidemiology of America. Prevention of influenza in long-term care facilities.
Infect Control Hosp Epidemiol 1999;20:629–37.
• Sneller V-P, Izurieta H, Bridges C, et al. Prevention and control of vaccine-
preventable diseases in long-term care facilities. J Am Med Directors Assoc
2000;1(Suppl):S2–37.
• American Academy of Pediatrics. 2000 red book: report of the Committee on
Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of
Pediatrics, 2000.
• CDC. 1999 USPHS/IDSA Guidelines for the prevention of opportunistic infections
in persons infected with human immunodeficiency virus. MMWR 1999;48(No. RR-
10):1–59.
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• CDC. General recommendations on immunization: recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR 1994;43(No. RR-
1):1–38.
• Bodnar UR, Maloney SA, Fielding KL, et al. Preliminary guidelines for the
prevention and control of influenza-like illness among passengers and crew
members on cruise ships. Atlanta, GA: US Department of Health and Human
Services, CDC, National Center for Infectious Diseases, 1999.
• CDC. General recommendations for preventing influenza A infection among
travelers. Atlanta, GA: US Department of Health and Human Services, CDC, 2001.
Available at <http://www.cdc.gov/travel/feb99.htm>. Accessed March 19, 2001.
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education credit. If you answer all of the questions, you will receive an award letter for 1.25 hour Continuing
Medical Education (CME) credit, 0.1 Continuing Education Unit (CEUs), or 1.3 contact hours Continuing Nursing
Education (CNE) credit. If you return the form electronically, you will receive educational credit immediately. If
you mail the form, you will receive educational credit in approximately 30 days. No fees are charged for
participating in this continuing education activity.
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1. Read this MMWR (Vol. 50, RR-4), which contains the correct answers to the questions beginning on the next
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answer will instruct you to “Indicate all that apply.”
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GOAL AND OBJECTIVES
This MMWR provides recommendations regarding the prevention and control of influenza. These recommendations
were developed by CDC staff and the Influenza Working Group of the Advisory Committee on Immunization
Practices (ACIP). The goal of this report is to provide guidance for the use of influenza vaccine and influenza
antiviral agents in the United States. Upon completion of this educational activity, the reader should be able to a)
describe the disease burden of influenza in the United States; b) describe the characteristics of the currently
licensed influenza vaccine; c) list the primary target groups for annual influenza vaccination; and d) recognize the
most common adverse reactions following administration of influenza vaccine.
To receive continuing education credit, please answer all of the following questions.
1. Which of the following statements is true concerning the burden of influenza in the
United States?
A. Rates of influenza virus infection are highest among children.
B. On average, >100,000 influenza-related hospitalizations occur each year.
C. Older adults account for >90% of deaths from influenza.
D. Pneumonia and influenza deaths have increased in recent years.
E. All of the above statements are true concerning the burden of influenza in the
United States.
2. What is the main option for reducing the impact of influenza in the United States?
A. Antibiotics.
B. Vitamin supplements.
C. Influenza vaccine.
D. Antiviral agents.
E. Improvement in indoor air quality.
3. Which of the following is true regarding influenza vaccine?
A. Influenza vaccine contains two strains of influenza virus.
B. Influenza vaccine viruses are grown in human diploid cell tissue culture.
C. Effectiveness of influenza vaccine is not influenced by the age of the recipient.
D. Influenza vaccine has been shown to be 70%–90% effective in preventing influenza
among healthy persons aged <65 years.
E. All the above statements are true regarding influenza vaccine.
4. Which of the following best describes the currently licensed influenza vaccine?
A. Inactivated virus.
B. Live attenuated virus.
C. Toxoid.
D. Protein conjugate.
E. Cloned DNA.
Vol. 50 / No. RR-4 MMWR CE-3
5. Which of the following groups should receive two doses of influenza vaccine during the
same season?
A. Persons with human immunodeficiency virus infection.
B. Elderly persons who reside in extended care facilities.
C. Unvaccinated children <9 years of age receiving influenza vaccine for the first time.
D. Health-care workers.
E. Adults aged >50 years.
6. Which of the following are among the primary target groups for annual influenza
vaccination?
A. Children with asthma.
B. Persons aged >50 years.
C. Health-care providers.
D. Women who will be in the second or third trimester of pregnancy during influenza
season.
E. All the above are among the primary target groups for annual influenza vaccination.
7. What is the most common adverse reaction following influenza vaccination?
A. Allergic reactions (e.g., angioedema).
B. Soreness at the injection site.
C. An illness identical to influenza.
D. Fever.
E. Guillain-Barré syndrome.
8. Which of the following conditions is a valid contraindication or precaution for the use of
influenza vaccine?
A. Current administration of antibiotics.
B. Breastfeeding.
C. Severe allergy to a component of the vaccine.
D. Recent administration of antibody-containing blood product (e.g., whole blood or
immunoglobulin).
E. All of the above are valid contraindications or precautions to the use of influenza
vaccine.
9. Which of the following statements is true concerning antiviral agents for influenza?
A. Influenza antiviral agents are approved only for the treatment of influenza A
infection.
B. Antiviral agents do not reduce the response to influenza vaccine.
C. All influenza antiviral agents are equally effective against influenza A and B viruses.
D. Treatment of influenza with antiviral agents requires a course of therapy of >14
days.
E. Antiviral agents have been shown to reduce the risk of serious influenza-related
complications.
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10. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
11. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.
C. Patient care — primary-care clinic or office.
D. Laboratory/pharmacy.
E. Public health.
F. Other.
12. I plan to use these recommendations as the basis for . . . (Indicate all that apply. )
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
13. Each fall, to approximately how many patients do you administer influenza vaccine?
A. None.
B. 1–5.
C. 6–20.
D. 21–50.
E. 51–100.
F. >100.
14. How much time did you spend reading this report and completing the exam?
A. <1 hour.
B. 1–1.5 hours.
C. 1.5–2 hours.
D. >2 hours.
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15. After reading this report, I am confident I can describe the disease burden of influenza in
the United States.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can describe the characteristics of the currently
licenced influenza vaccine.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can list the primary target groups for annual
influenza vaccination.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can recognize the most common adverse
reactions following administration of influenza vaccine.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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20. The tables are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR  cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR subscription.
F. Other.
Correct answers for questions 1–9
1. E; 2. C; 3. D; 4. A; 5. C; 6. E; 7. B; 8. C; 9. B.
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